165 related articles for article (PubMed ID: 33108504)
1. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
[TBL] [Abstract][Full Text] [Related]
2. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
[TBL] [Abstract][Full Text] [Related]
5. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
Kuchimanchi M; Dabrowski C; Lu S; Melhem M
Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Fernández-Teruel C; Lubomirov R; Fudio S
J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
[TBL] [Abstract][Full Text] [Related]
9. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Garg A; Li J; Clark E; Knott A; Carrothers TJ; Marier JF; Cortés J; Brewster M; Visich J; Lum B
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1133-41. PubMed ID: 23999693
[TBL] [Abstract][Full Text] [Related]
10. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
11. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Hoffman J; Chakrabarti J; Plotka A; Milillo Naraine A; Kanamori D; Moroose R; Nguyen L; Wang D; Wainberg ZA
Anticancer Drugs; 2019 Jun; 30(5):523-532. PubMed ID: 30875341
[TBL] [Abstract][Full Text] [Related]
12. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
13. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
[TBL] [Abstract][Full Text] [Related]
14. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Quinlan M; Zhou J; Hurh E; Sellami D
Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
19. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
[TBL] [Abstract][Full Text] [Related]
20. Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
Fernandez-Teruel C; Gonzalez I; Trocóniz IF; Lubomirov R; Soto A; Fudio S
Clin Pharmacokinet; 2019 Mar; 58(3):363-374. PubMed ID: 30090974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
